当前位置: 易推广 > 生物试剂/抗体/细胞 > 生化试剂 > 其他 > MedChemExpress > 产品展示 > 抗体抑制剂 > Vobramitamab duocarmazine
Vobramitamab duocarmazine
企业档案
会员类型:会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累,可浏览访问
(41-90)良好信誉积累,可接洽商谈
(91+ )优质信誉积累,可持续信赖
易推广会员:8年
最后认证时间:
注册号: 【已认证】
法人代表: 【已认证】
企业类型:生产商 【已认证】
注册资金:人民币万 【已认证】
产品数:91196
参观次数:10550938
联系我们
MedChemExpress
电话:021-58955995
联系人:客服部 (请说明是在易推广看到的!谢谢)
手机:13611715263
邮编:201203
邮箱:sales@medchemexpress.cn
地址:上海上海
详细内容
MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务。
Vobramitamab duocarmazine
CAS No. : 2490556-51-7
MCE 站:Vobramitamab duocarmazine
产品活性:Vobramitamab duocarmazine (AEX4089DC1; MGC018),一种靶向 B7-H3 (CD276) 的人源化抗体-药物偶联物 (ADC) (Antibody-Drug Conjugates (ADCs))。Vobramitamab duocarmazine 由可裂解接头-Duocarmycin 有效负载,Vc-seco-DUBA (Vc-seco-DUBA (HY-128957)),与抗 B7-H3 人源化 IgG1κ 单克隆抗体偶联。Vobramitamab duocarmazine 具有抗肿瘤活性。
研究领域:Antibody-drug Conjugate/ADC Related
作用靶点:Antibody-Drug Conjugates (ADCs)
In Vitro: Vobramitamab duocarmazine (MGC018; for 7 days) exhibits cytotoxicity toward B7-H3-positive human tumor cell lines, including MDA-MB-468, A375.S2, PA-1, Calu-6, NCI-H1703, Hs700T, LN-229, and SW48 cancer cells, with IC50 values range of 181-1447 pM. Vobramitamab duocarmazine exhibited bystander killing of target-negative tumor cells when cocultured with B7-H3-positive tumor cells.
In Vivo: Vobramitamab duocarmazine (MGC018; 3-6 mg/kg; i.v; single-dose) leads to a dose-dependent decrease in tumor growth of MDA-MB-468 triple-negative breast cancer xenografts.
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) leads to a rapid tumor regression, with a 98% reduction in tumor volume in a triple-negative breast cancer patient-derived xenograft (PDX) model.
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) shows antitumor activity in the PA-1 ovarian cancer xenografts. A reduction in tumor volume of 89%, 91%, and 43%, is observed following treatment with Vobramitamab duocarmazine at 10, 6, and 3 mg/kg, respectively.
Vobramitamab duocarmazine (MGC018; 1-3 mg/kg; i.v; single-dose) shows antitumor activity in A375.S2 melanoma xenografts.
Vobramitamab duocarmazine (MGC018; 3-10 mg/kg; i.v; single-dose) shows antitumor activity in Calu-6 lung cancer xenografts. A reduction in tumor volume of 91%, 84%, and 72% is observed following treatment with Vobramitamab duocarmazine at 10 mg/kg, 6 mg/kg, and 3 mg/kg, respectively.
Vobramitamab duocarmazine (MGC018; 3 mg/kg; QW×3 or Q2W×2; i.v) shows antitumor activity toward patient-derived xenograft models of prostate, and head and neck cancer displaying heterogeneous expression of B7-H3.
相关产品:Enfortumab vedotin-ejfv | Sacituzumab govitecan | Anetumab ravtansine | Trastuzumab deruxtecan | Belantamab mafodotin | Trastuzumab emtansine | Brentuximab vedotin | Disitamab vedotin | Mal-VC-PAB-(N-Me-amide-C3)-ADU-S100 triethylamine | Aprutumab ixadotin
热门产品线:重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物 | 寡核苷酸
Trending products:Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
品牌介绍:
• MCE (MedChemExpress) 拥有数百种全球独家化合物,我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物;
• 40,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域;
• 设有专业的实验中心和严格的质控、验证体系;
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告,确保产品的高纯度、高品质;
• 产品的生物活性多经各国客户实验验证;
• Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果;
• 专业团队跟踪*新的制药及生命科学研究进展,为您提供全球*新的活性化合物;
• 与世界各大制药公司及知名科研机构建立了长期的合作。
热门标签:AEX4089DC1